Phase 2Recruiting
Pan Tumor Rollover Study
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies
- Sponsor
- Bristol-Myers Squibb (Industry)
- Enrollment
- 1,500 planned
- Conditions
- Cancer
- Interventions
- Nivolumab; Ipilimumab; Cabozantinib; Trametinib; Relatlimab; Nivolumab + Relatlimab; Capecitabine; Bevacizumab; Temozolomide; Rucaparib; Daratumumab; Regorafinib
- Ages
- adults, older adults
- Registry
- NCT03899155, EUCTR2018-004362-34
Full record on ClinicalTrials.gov
From the registry
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Primary outcomes
- Incidence of Adverse Events (AEs)
- Incidence of drug related AEs
- Incidence of AEs leading to Discontinuation
- Incidence of Serious Adverse Events (SAEs)
History
Primary completion expected
Last registry update
Started
Registered